You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The blood-based test is designed to detect changes in levels of microRNAs that are enriched in specific brain regions affected by Alzheimer's disease.
In PLOS this week: microRNA expression changes in hepatocellular carcinoma, real-time PCR-based approach for diagnosing schistosomiasis, and more.
In PLOS this week: deletion in NME5 linked to primary ciliary dyskinesia in Alaskan Malamutes, study of rabies virus movement in Ontario, and more.
The platform is designed to isolate exosomes from blood, then release their extracellular RNA cargo for analysis as biomarkers for diseases including cancer.
The company missed the analysts' average estimates on the top and bottom lines, but it raised its full-year 2019 revenue guidance.
An international team documented TP53 mutation-related genomic changes across dozens of cancer types using data generated with five platforms for the Cancer Genome Atlas project.
Mirnax will use Arcis' nucleic acid sample preparation and preservation technology to improve the stability of miRNA biomarkers for early disease detection.
The firm is applying the isolation tool in cellular therapy for oral cancer by administering a biomarker via bioengineered exosomes to reverse cancer progression.
In PLOS this week: alternatively spliced form of FBXO38 contributes to chronic obstructive pulmonary disease, evolution of the avian influenza virus H9N2, and more.
The funding will be used to support clinical validation and expand market access for the firm's endometriosis diagnostic test.
Master's and doctoral students in the UK call on funding groups to extend their grants for the duration of the disruption caused by the COVID-19 outbreak, the Guardian reports.
Squid can make edits to their RNA within the cytoplasm of their axons, Science News reports.
The Chan Zuckerberg Initiative is putting $25 million toward COVID-19 treatment research, according to the Verge.
In Science this week: researchers engineer version of Cas9 that is nearly PAM-less, and more.